DE60139429D1 - Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren - Google Patents
Pyrimidin-5-Onderivate als LDL-PLA2 InhibitorenInfo
- Publication number
- DE60139429D1 DE60139429D1 DE60139429T DE60139429T DE60139429D1 DE 60139429 D1 DE60139429 D1 DE 60139429D1 DE 60139429 T DE60139429 T DE 60139429T DE 60139429 T DE60139429 T DE 60139429T DE 60139429 D1 DE60139429 D1 DE 60139429D1
- Authority
- DE
- Germany
- Prior art keywords
- onderivatives
- ldl
- pyrimidine
- pla2 inhibitors
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0003636A GB0003636D0 (en) | 2000-02-16 | 2000-02-16 | Novel compounds |
GB0101437A GB0101437D0 (en) | 2001-01-19 | 2001-01-19 | Novel Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60139429D1 true DE60139429D1 (de) | 2009-09-10 |
Family
ID=26243663
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60139429T Expired - Lifetime DE60139429D1 (de) | 2000-02-16 | 2001-02-13 | Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren |
DE60121550T Expired - Lifetime DE60121550T2 (de) | 2000-02-16 | 2001-02-13 | Pyrimidin-4-onderivat als LDL-PLA2 Inhibitor |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60121550T Expired - Lifetime DE60121550T2 (de) | 2000-02-16 | 2001-02-13 | Pyrimidin-4-onderivat als LDL-PLA2 Inhibitor |
Country Status (32)
Country | Link |
---|---|
US (10) | US20020103213A1 (de) |
EP (2) | EP1686119B1 (de) |
JP (1) | JP4095804B2 (de) |
KR (1) | KR100781425B1 (de) |
CN (1) | CN1179952C (de) |
AR (1) | AR030190A1 (de) |
AT (2) | ATE437862T1 (de) |
AU (2) | AU3546601A (de) |
BG (1) | BG66014B1 (de) |
BR (1) | BRPI0108396B1 (de) |
CA (1) | CA2400554C (de) |
CO (1) | CO5271661A1 (de) |
CY (2) | CY1105649T1 (de) |
CZ (1) | CZ304450B6 (de) |
DE (2) | DE60139429D1 (de) |
DK (2) | DK1686119T3 (de) |
ES (2) | ES2267714T3 (de) |
GC (1) | GC0000221A (de) |
HK (1) | HK1053466A1 (de) |
HU (1) | HU229479B1 (de) |
IL (2) | IL151236A (de) |
MX (1) | MXPA02008062A (de) |
MY (1) | MY135732A (de) |
NO (1) | NO324691B1 (de) |
NZ (1) | NZ520752A (de) |
PL (1) | PL209824B1 (de) |
PT (2) | PT1686119E (de) |
SI (2) | SI1686119T1 (de) |
SK (1) | SK287296B6 (de) |
TW (1) | TW550259B (de) |
UA (1) | UA73762C2 (de) |
WO (1) | WO2001060805A1 (de) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ304450B6 (cs) * | 2000-02-16 | 2014-05-14 | Smithkline Beecham P. L. C. | Pyrimidinový derivát |
GB0024807D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
PL361887A1 (en) * | 2000-10-20 | 2004-10-04 | Biovitrum Ab | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy |
GB0119795D0 (en) | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel process |
GB0119793D0 (en) * | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
GB0127141D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham Plc | Novel compounds |
GB0127140D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0127143D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0127139D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
EP1466904A4 (de) * | 2001-12-28 | 2005-12-14 | Takeda Pharmaceutical | Biarylverbindung und dessen verwendung |
US6939863B2 (en) | 2002-01-04 | 2005-09-06 | Wei-Jan Chen | Prevention of atherosclerosis and restenosis |
GB0208279D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
GB0208280D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
US20050227974A9 (en) * | 2002-08-01 | 2005-10-13 | Euro-Celtique S.A. | Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers |
JP4366122B2 (ja) * | 2003-06-24 | 2009-11-18 | 日立オムロンターミナルソリューションズ株式会社 | 紙葉類搬送装置 |
GB0320522D0 (en) * | 2003-09-02 | 2003-10-01 | Glaxo Group Ltd | Formulation |
EP2314576A1 (de) | 2003-11-05 | 2011-04-27 | F.Hoffmann-La Roche Ag | Phenylderivate zur Verwendung als PPAR-Agonisten |
US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
US7741020B2 (en) | 2004-04-16 | 2010-06-22 | Glaxo Group Limited | Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity |
WO2005110416A2 (en) | 2004-05-08 | 2005-11-24 | Neurogen Corporation | 4,5-disubstituted-2-aryl pyrimidines |
DE102004061005A1 (de) * | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | 3-Cycloalkyl-1,2,4-triazin-5(2H)-one |
US20080090851A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
US7705005B2 (en) * | 2006-10-13 | 2010-04-27 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
US20080090852A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
AU2008251467B2 (en) * | 2007-05-11 | 2014-07-31 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
BRPI0721697A2 (pt) * | 2007-05-11 | 2014-08-05 | Univ Jefferson | " métodos para tratar e/ou prevenir uma doença ou distúrbio neurodegenerativo em um indivíduo, para tratar e/ou prevenir um indivíduo com ou em risco de demência vascular, para tratar e/ou prevenir uma doença ou distúrbio associado com uma barreira hematoencefálica anormal em um indivíduo, para diminuir o acúmulo beta amilóide no cérebro de um indivíduo, para tratar e/ou prevenir mal de alzheimer em um indivíduo e para prevenir ou reduzir o risco de desenvolver mal de alzhheimer, e, uso de um agente que inibe a expressão e/ou atividade da proteína lp-pla2." |
US8637524B2 (en) | 2009-07-28 | 2014-01-28 | Auspex Pharmaceuticals, Inc | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 |
TW201209043A (en) * | 2010-05-17 | 2012-03-01 | Glaxo Group Ltd | Novel processes |
KR101931628B1 (ko) | 2010-06-18 | 2019-03-13 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | 항바이러스 화합물에 대한 타켓인 pla2g16 |
WO2012076435A1 (en) * | 2010-12-06 | 2012-06-14 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2 |
EP2649050A4 (de) * | 2010-12-06 | 2014-04-23 | Glaxo Group Ltd | Verbindungen |
CN104478812A (zh) * | 2010-12-06 | 2015-04-01 | 葛兰素集团有限公司 | 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物 |
WO2012080497A2 (en) | 2010-12-17 | 2012-06-21 | Glaxo Group Limited | Methods of treatment and prevention of eye diseases |
CN102643269B (zh) * | 2011-02-21 | 2014-07-23 | 天津药物研究院 | 一类含吡唑结构的磷脂酶a2抑制剂及用途 |
WO2012122707A1 (zh) * | 2011-03-16 | 2012-09-20 | 中国科学院上海药物研究所 | 季铵盐类化合物、其制备方法、药物组合物及用途 |
WO2012129792A1 (zh) * | 2011-03-30 | 2012-10-04 | 中国科学院上海药物研究所 | 嘧啶酮类化合物、其制备方法及药物组合物和用途 |
WO2013000267A1 (zh) | 2011-06-27 | 2013-01-03 | 中国科学院上海药物研究所 | 唑类杂环化合物、其制备方法、药物组合物和用途 |
BR112014001665A2 (pt) | 2011-07-27 | 2017-02-14 | Glaxo Group Ltd | compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz |
TW201321382A (zh) | 2011-07-27 | 2013-06-01 | Glaxo Group Ltd | 化合物 |
CN103827116B (zh) * | 2011-07-27 | 2016-08-31 | 葛兰素集团有限公司 | 用作LP-PLA2抑制剂的2,3-二氢咪唑并[1,2-c]嘧啶-5(1H)-酮化合物 |
KR20150111356A (ko) | 2013-01-25 | 2015-10-05 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 화합물 |
UY35276A (es) | 2013-01-25 | 2014-08-29 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos que inhiben la actividad de Lp-PLA2 |
BR112015017397A2 (pt) | 2013-01-25 | 2017-07-11 | Glaxosmithkline Ip Dev Ltd | compostos pirimidona bicíclica como inibidores de lp-pla2 |
US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
WO2015087239A1 (en) | 2013-12-11 | 2015-06-18 | Ranbaxy Laboratories Limited | Processes for the preparation of darapladib and its intermediates |
WO2015092687A2 (en) | 2013-12-17 | 2015-06-25 | Ranbaxy Laboratories Limited | Process for the purification of darapladib |
WO2015114479A1 (en) | 2014-01-28 | 2015-08-06 | Ranbaxy Laboratories Limited | Crystalline forms of darapladib oxalate, adipate, succinate, phosphate, sulphate, fumaratetartrate, nitrate and borate |
WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
EP3186242B1 (de) | 2014-08-29 | 2021-10-06 | Tes Pharma S.r.l. | Inhibitoren von alpha-amino-beta-carboxymuconsäure semialdehyd-decarboxylase |
CN105777653A (zh) * | 2014-12-26 | 2016-07-20 | 中国科学院上海药物研究所 | 用作Lp-PLA2抑制剂的嘧啶酮类化合物及其药物组合物 |
CN104840963B (zh) * | 2015-05-26 | 2018-02-16 | 河北东康生物科技有限公司 | 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用 |
US10464896B2 (en) * | 2015-06-11 | 2019-11-05 | Basilea Pharmaceutica International AG | Efflux-pump inhibitors and therapeutic uses thereof |
UY37026A (es) * | 2015-12-16 | 2017-06-30 | Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj |
US10878307B2 (en) * | 2016-12-23 | 2020-12-29 | Microsoft Technology Licensing, Llc | EQ-digital conversation assistant |
US11583596B2 (en) | 2017-09-26 | 2023-02-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Radiolabeled Darapladib and analogs thereof and their use as imaging compounds |
CN110746445B (zh) * | 2019-10-16 | 2021-03-16 | 深圳海关食品检验检疫技术中心 | 一种头孢哌酮氘代内标物的制备方法 |
MX2022005615A (es) | 2019-11-09 | 2022-07-27 | Shanghai Simr Biotechnology Co Ltd | Derivado triciclico de dihidroimidazopirimidona, metodo de preparacion del mismo, composicion farmaceutica y uso del mismo. |
CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
EP4257133A1 (de) | 2022-04-05 | 2023-10-11 | Institut Pasteur | Oxo-azaheterozyklische derivate zur verwendung bei der behandlung von malaria |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69423436T2 (de) | 1993-06-25 | 2000-09-07 | Smithkline Beecham Plc | An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie |
ES2159573T3 (es) * | 1993-10-06 | 2001-10-16 | Icos Corp | Acetilhidrolasa del factor activador de plaquetas. |
GB9421816D0 (en) | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
JPH11500415A (ja) | 1994-12-22 | 1999-01-12 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アテローム性動脈硬化症治療用置換アゼチジン−2−オン |
CH690264A5 (fr) | 1995-06-30 | 2000-06-30 | Symphar Sa | Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques. |
AP728A (en) | 1995-07-01 | 1999-01-29 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis. |
JP2002515728A (ja) | 1995-09-29 | 2002-05-28 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 新規用途 |
JP2000505063A (ja) | 1995-12-08 | 2000-04-25 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アテローム性動脈硬化症の治療のためのアゼチジノン化合物 |
EP0869943A1 (de) | 1995-12-08 | 1998-10-14 | Smithkline Beecham Plc | Monocyclische beta-lactame zur behandlung von atherosklerose |
GB9608649D0 (en) | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
HUP9901359A3 (en) | 1996-04-26 | 2000-03-28 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them |
GB9626536D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
GB9626615D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
GB9626616D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
US6417192B1 (en) * | 1997-11-06 | 2002-07-09 | Smithkline Beecham P.L.C. | Pyrimidinone compounds and pharmaceutical compositions containing them |
WO2000010980A1 (en) | 1998-08-21 | 2000-03-02 | Smithkline Beecham Plc | Pyrimidinone derivatives for the treatment of atherosclerosis |
SI1175408T1 (en) | 1999-05-01 | 2005-04-30 | Smithkline Beecham Plc | Pyrimidinone compounds |
GB9910079D0 (en) | 1999-05-01 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
GB9910378D0 (en) | 1999-05-05 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
CZ304450B6 (cs) * | 2000-02-16 | 2014-05-14 | Smithkline Beecham P. L. C. | Pyrimidinový derivát |
GB0024807D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
GB0024808D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
-
2001
- 2001-02-13 CZ CZ2002-2768A patent/CZ304450B6/cs not_active IP Right Cessation
- 2001-02-13 WO PCT/EP2001/001515 patent/WO2001060805A1/en active Application Filing
- 2001-02-13 JP JP2001560190A patent/JP4095804B2/ja not_active Expired - Fee Related
- 2001-02-13 AU AU3546601A patent/AU3546601A/xx active Pending
- 2001-02-13 SK SK1177-2002A patent/SK287296B6/sk not_active IP Right Cessation
- 2001-02-13 SI SI200130941T patent/SI1686119T1/sl unknown
- 2001-02-13 KR KR1020027010662A patent/KR100781425B1/ko not_active IP Right Cessation
- 2001-02-13 AU AU2001235466A patent/AU2001235466B2/en not_active Ceased
- 2001-02-13 NZ NZ520752A patent/NZ520752A/en not_active IP Right Cessation
- 2001-02-13 ES ES01907522T patent/ES2267714T3/es not_active Expired - Lifetime
- 2001-02-13 EP EP06075890A patent/EP1686119B1/de not_active Expired - Lifetime
- 2001-02-13 ES ES06075890T patent/ES2330552T3/es not_active Expired - Lifetime
- 2001-02-13 PL PL357382A patent/PL209824B1/pl unknown
- 2001-02-13 CA CA002400554A patent/CA2400554C/en not_active Expired - Fee Related
- 2001-02-13 EP EP01907522A patent/EP1263740B1/de not_active Expired - Lifetime
- 2001-02-13 AT AT06075890T patent/ATE437862T1/de active
- 2001-02-13 MX MXPA02008062A patent/MXPA02008062A/es active IP Right Grant
- 2001-02-13 DK DK06075890T patent/DK1686119T3/da active
- 2001-02-13 CN CNB01806521XA patent/CN1179952C/zh not_active Expired - Fee Related
- 2001-02-13 BR BRPI0108396-1A patent/BRPI0108396B1/pt not_active IP Right Cessation
- 2001-02-13 AT AT01907522T patent/ATE333446T1/de active
- 2001-02-13 DE DE60139429T patent/DE60139429D1/de not_active Expired - Lifetime
- 2001-02-13 SI SI200130614T patent/SI1263740T1/sl unknown
- 2001-02-13 DE DE60121550T patent/DE60121550T2/de not_active Expired - Lifetime
- 2001-02-13 UA UA2002097389A patent/UA73762C2/uk unknown
- 2001-02-13 HU HU0204410A patent/HU229479B1/hu not_active IP Right Cessation
- 2001-02-13 DK DK01907522T patent/DK1263740T3/da active
- 2001-02-13 PT PT06075890T patent/PT1686119E/pt unknown
- 2001-02-13 PT PT01907522T patent/PT1263740E/pt unknown
- 2001-02-14 AR ARP010100659A patent/AR030190A1/es not_active Application Discontinuation
- 2001-02-14 US US09/782,930 patent/US20020103213A1/en not_active Abandoned
- 2001-02-14 MY MYPI20010671A patent/MY135732A/en unknown
- 2001-02-14 GC GCP20011178 patent/GC0000221A/en active
- 2001-02-15 TW TW090103332A patent/TW550259B/zh not_active IP Right Cessation
- 2001-02-15 CO CO01011957A patent/CO5271661A1/es active IP Right Grant
-
2002
- 2002-08-13 IL IL151236A patent/IL151236A/en not_active IP Right Cessation
- 2002-08-13 NO NO20023828A patent/NO324691B1/no not_active IP Right Cessation
- 2002-08-26 BG BG107034A patent/BG66014B1/bg unknown
-
2003
- 2003-02-03 US US10/357,238 patent/US6649619B1/en not_active Expired - Lifetime
- 2003-06-09 HK HK03104052A patent/HK1053466A1/xx not_active IP Right Cessation
- 2003-10-27 US US10/694,561 patent/US7153861B2/en not_active Expired - Fee Related
-
2006
- 2006-10-06 CY CY20061101441T patent/CY1105649T1/el unknown
- 2006-11-17 US US11/561,035 patent/US7470694B2/en not_active Expired - Fee Related
- 2006-11-21 US US11/561,926 patent/US7638520B2/en not_active Expired - Fee Related
-
2007
- 2007-03-15 IL IL181957A patent/IL181957A0/en unknown
-
2009
- 2009-01-06 US US12/349,086 patent/US7652019B2/en not_active Expired - Fee Related
- 2009-02-18 US US12/372,837 patent/US20090170877A1/en not_active Abandoned
- 2009-10-12 CY CY20091101045T patent/CY1109484T1/el unknown
-
2010
- 2010-02-18 US US12/707,838 patent/US20100144765A1/en not_active Abandoned
-
2011
- 2011-12-02 US US13/309,941 patent/US8871775B2/en not_active Expired - Fee Related
-
2014
- 2014-10-24 US US14/522,870 patent/US9266841B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60139429D1 (de) | Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren | |
BR0010220A (pt) | Compostos de pirimidinona | |
DK1070056T3 (da) | Phthalazinon-PDE III/IV-inhibitorer | |
PT1465864E (pt) | Inibidores de factor xa e outras serina proteases envolvidos na cascata da coagulacao | |
ATE461171T1 (de) | Neue mandelsäurederivate und deren verwendung als thrombininhibitoren | |
DE60133897D1 (de) | Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren | |
DE69939168D1 (de) | Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung | |
ATE323072T1 (de) | Pyrimidin-derivate als selective inhibitoren von cox-2 | |
ATE495736T1 (de) | Verwendung von derivaten der 2-oxothiazolidin-4- corbonsäure als prä-abschuppungsmittel | |
BR0209149A (pt) | Ftalazinonas | |
DE60219068D1 (de) | Substituierte 2-amino-zykloalkankarboxamide und ihre verwendung als zysteinprotease-inhibitoren | |
DE60016629D1 (de) | Ox(adi)azoly-hydroxamsäuren und ihre verwendung als prokollagen c-proteinase inhibitoren | |
ATE305787T1 (de) | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren | |
ATE258930T1 (de) | Dihydrobenzifurane | |
DE69915686D1 (de) | Amidinoderivate und ihre verwendung als thrombin-inhibitoren | |
FR2816843B1 (fr) | Inhibiteurs de l'enzyme 5 alpha-reductase | |
ATE287403T1 (de) | 6-phenylbenzonaphthyidine | |
DE50211985D1 (de) | Verwendung von pyridin-2,4-dicarbons urediamiden und pyrimid in-4,6-dicarbons urediamiden zur selektiven inhibierung von kollagenasen | |
DE60036558D1 (de) | Phthalazinon-derivate als pde 4 hemmer | |
BR0114884A (pt) | Compostos calcilìticos | |
ATE227288T1 (de) | Acetylenische ortho-sulfonamido- und phosphinsäure-amido-bicyclische heteroarylhydroxamsäure als tace-inhibitoren | |
DE60319743D1 (de) | Phthalazinderivate als phosphodiesterase-4-hemmer | |
DK1075476T3 (da) | Hidtil ukendte benzimidazoler og benzoxazoler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |